From [CHD] The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,226,314 reports of adverse events following COVID vaccines were submitted between Dec. 14, 2020, and April 8, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 26,976 reports of deaths — an increase of 277 over the previous week — and 219,865 serious injuries, including deaths, during the same time period — up 2,564 compared with the previous week.

Excluding “foreign reports” to VAERS, 805,921 adverse events, including 12,471 deaths and 79,811 serious injuries, were reported in the U.S. between Dec. 14, 2020, and April 8, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 12,471 U.S. deaths reported as of April 8, 17% occurred within 24 hours of vaccination, 21% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 564 million COVID vaccine doses had been administered as of April 8, including 334 million doses of Pfizer, 212 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

U.S. VAERS data from Dec. 14, 2020, to April 8, 2022, for 5- to 11-year-olds show:

• 10,216 adverse events, including 242 rated as serious and 5 reported deaths.

• 18 reports of myocarditis and pericarditis (heart inflammation).
  The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.

• 39 reports of blood clotting disorders.

U.S. VAERS data from Dec. 14, 2020, to April 8, 2022, for 12- to 17-year-olds show:

• 31,048 adverse events, including 1,792 rated as serious and 44 reported deaths.

• 67 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.

• 651 reports of myocarditis and pericarditis, with 639 cases attributed to Pfizer’s vaccine.

• 166 reports of blood clotting disorders, with all cases attributed to Pfizer.

U.S. VAERS data from Dec. 14, 2020, to April 8, 2022, for all age groups combined, show:

• 20% of deaths were related to cardiac disorders.

• 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.

• The average age of death was 73.

• As of April 8, 5,404 pregnant women reported adverse events related to COVID vaccines, including 1,696 reports of miscarriage or premature birth.

• Of the 3,647 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.

• 860 reports of Guillain-Barré syndrome, with 42% of cases attributed to Pfizer, 30% to Moderna and 28% to J&J.

• 2,373 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.

• 1,671 reports of myocardial infarction.

• 13,755 reports of blood-clotting disorders in the U.S. Of those, 6,169 reports were attributed to Pfizer, 4,911 reports to Moderna and 2,654 reports to J&J.

• 4,124 cases of myocarditis and pericarditis with 2,531 cases attributed to Pfizer, 1,402 cases to Moderna and 181 cases to J&J’s COVID vaccine.

Woman develops fatal brain disease after second Moderna dose

Carol Beauchine died from sporadic Creutzfeldt-Jakob Disease (CJD), a rapidly evolving, fatal degenerative brain disorder she developed after her second dose of Moderna’s COVID vaccine.

In an exclusive interview with The Defender, Carol’s son, Jeffrey Beauchine, said it was excruciating to watch his 70-year-old mother — who was healthy until she got the vaccine — die from a disease he believes the vaccine caused.

Beauchine said Carol received her first dose of Moderna on Feb. 16, 2021, and didn’t report any complaints. After getting the second dose on March 17, Carol immediately said she “felt different.” She developed numbness that spread throughout the entire left side of her body, blindness and hearing loss. She lost the ability to walk and communicate, and her brain degenerated until she passed away on Aug. 2, 2021 — just five months after receiving her second dose of Moderna.

The family submitted a report to VAERS, but the CDC has not followed up on Carol’s death. The Defender has received numerous reports of people who died from sporadic CJD after receiving a COVID vaccine — all women who were between the ages of 60 and 70, including Cheryl Cohenand Jennifer Deason Sprague.

Biden administration extends COVID public health emergency needed to keep vaccines under EUA

The Biden administration on Wednesday extended the COVID public health emergency, now two years old, for an additional 90 days — allowing vaccines and other drugs to remain under Emergency Use Authorization (EUA). Keeping COVID vaccines and other countermeasures under EUA shields pharmaceutical companies from liability for the harms caused by their products.

According to Reuters, a public health emergency was initially announced in January 2020, when the COVID pandemic began. It has been renewed each quarter since and was due to expire on April 16.

The Department of Health and Human Services (HHS) said in a statement it was extending the public health emergency and will give states 60 days’ notice prior to termination or expiration. This may be the last time HHS Secretary Xavier Becerra extends it, according to policy experts.